Journal Watch · Frontiers in Immunology · 2026
Regulatory T cells in primary sjögren disease: regulatory mechanisms and therapeutic prospects.
This review summarizes the regulatory mechanisms of Tregs in SjD based on recent literature and explores the potential of Treg-targeted therapeutic strategies for SjD, aiming to provide a theoretical basis for the development of novel treatment approaches for this disease.
TL;DR
This review summarizes the regulatory mechanisms of Tregs in SjD based on recent literature and explores the potential of Treg-targeted therapeutic strategies for SjD, aiming to provide a theoretical basis for the development of novel treatment approaches for this disease.
Key findings
- These interventions synergistically reduce inflammatory responses, downregulate abnormal immune activation, and alleviate tissue pathological damage, ultimately leading to significantly increased saliva and tear secretion.
- This review summarizes the regulatory mechanisms of Tregs in SjD based on recent literature and explores the potential of Treg-targeted therapeutic strategies for SjD, aiming to provide a theoretical basis for the development of novel treatment approaches for this disease.
What they did
They are also critically involved in the pathogenesis and progression of various autoimmune diseases, including SjD. Consequently, modulating the proliferation, activation, and functional balance of Tregs holds significant promise for ameliorating the immune-inflammatory microenvironment in SjD and slowing disease progression. Recent studies have shown that mesenchymal stem cells (MSCs), fenofibrate, and metformin can promote Treg proliferation and improve their function, thereby restoring the Th17/Treg immune balance.
Full abstract (original)
Background: Primary Sjögren disease (SjD) is a chronic inflammatory autoimmune disorder characterized by lymphocyte proliferation and progressive damage to exocrine glands. Its pathogenesis is complex, and clinical treatment remains challenging. Regulatory T cells (Tregs), a subset of inhibitory T lymphocytes, play a pivotal role in maintaining peripheral immune tolerance and immune homeostasis.
What they did: They are also critically involved in the pathogenesis and progression of various autoimmune diseases, including SjD. Consequently, modulating the proliferation, activation, and functional balance of Tregs holds significant promise for ameliorating the immune-inflammatory microenvironment in SjD and slowing disease progression. Recent studies have shown that mesenchymal stem cells (MSCs), fenofibrate, and metformin can promote Treg proliferation and improve their function, thereby restoring the Th17/Treg immune balance.
Results & conclusions: These interventions synergistically reduce inflammatory responses, downregulate abnormal immune activation, and alleviate tissue pathological damage, ultimately leading to significantly increased saliva and tear secretion. This review summarizes the regulatory mechanisms of Tregs in SjD based on recent literature and explores the potential of Treg-targeted therapeutic strategies for SjD, aiming to provide a theoretical basis for the development of novel treatment approaches for this disease.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1802660 · PubMed 42064052.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
This review summarizes the regulatory mechanisms of Tregs in SjD based on recent literature and explores the potential of Treg-targeted therapeutic strategies for SjD, aiming to provide a theoretical basis for the development of novel treatment approaches for this disease.
What type of study is this?
It is a review / perspective, published in Frontiers in Immunology in 2026. They are also critically involved in the pathogenesis and progression of various autoimmune diseases, including SjD.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1802660. PubMed ID: 42064052. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/regulatory-t-cells-in-primary-sjogren-disease-regulatory-mechanisms-and-802660/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides